We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesGland Pharma Limited

Gland Pharma Limited

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
3308.3999 INR 44.50 ( 1.36%)
Last update at 2026-11-12T09:46:00Z
VOLUME
217540
Market Cap
281733.46M
P/E
35.62

Momentum Score

…

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3268.50
Low
3347.00
High
52 Week Price Range
1266.01
Low
2111.33
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3263.90
Dividend Yield
-
Revenue TTM
58014.58M
Revenue Per Share
352.18
Gross Profit TTM
34001.71M
Debt / Equity
0.03
ROE
8.61%
Net Debt
-22424.76M
ROCE
9.03%
Diluted EPS TTM
48.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax 10626.58M 11325.42M 10545.82M 16185.52M 13348.10M
Minority interest 0.00M 0.00M 0.00M 0.00M 0.00M
Net income 6985.26M 7724.60M 7810.43M 12116.64M 9969.63M
Selling general administrative 1136.39M 1324.43M 485.32M 313.62M 162.70M
Selling and marketing expenses 274.82M 374.64M 270.32M 409.81M 366.94M
Gross profit 31543.74M 31108.10M 19391.74M 22749.28M 19317.63M
Reconciled depreciation 3778.74M 3445.66M 1467.36M 1102.96M 987.80M
Ebit 8721.30M 9714.71M 11184.90M 16179.85M 13379.73M
Ebitda 12314.04M 12968.07M 12652.26M 17282.81M 14367.53M
Depreciation and amortization 3592.74M 3253.36M 1467.36M 1102.96M 987.80M
Operating income 17377.56M 18225.72M 8844.40M 14000.34M 12034.45M
Other operating expenses 38787.48M 38421.50M 27465.74M 29837.69M 22199.16M
Interest expense 239.87M 262.00M 74.47M 34.02M 29.11M
Tax provision 3641.32M 3600.82M 2735.39M 4068.88M 3378.47M
Interest income 2042.78M 1506.05M 1794.17M 1386.45M 859.49M
Net interest income -420.00M -262.00M -74.47M -52.42M -34.11M
Income tax expense 3641.32M 3600.82M 2735.39M 4068.88M 3378.47M
Total revenue 56165.04M 56647.22M 36246.01M 43841.45M 34236.37M
Total operating expenses 14166.18M 12882.38M 10611.47M 8745.52M 7280.42M
Cost of revenue 24621.30M 25539.12M 16854.27M 21092.17M 14918.74M
Total other income expense net -6750.98M -6900.30M 1701.42M 2185.18M 1313.65M
Net income from continuing ops 6985.26M 7724.60M 7810.43M 12116.64M 9969.63M
Net income applicable to common shares - - - 12116.64M 9969.63M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 112249.20M 106612.46M 87775.35M 78336.21M 64960.82M
Intangible assets 1057.02M 1122.19M 116.61M 125.35M 125.35M
Other current assets 6289.93M 3818.61M 2477.79M 1722.29M 1292.91M
Total liab 20741.79M 19374.03M 8188.13M 6760.00M 5928.40M
Total stockholder equity 91507.41M 87238.43M 79587.22M 71576.21M 59032.42M
Other current liab 5378.53M 1677.12M 924.66M 552.57M 63.25M
Common stock 164.76M 164.71M 164.70M 164.30M 163.59M
Capital stock 164.76M 164.71M 164.70M 164.30M 163.59M
Retained earnings 71568.71M 67878.48M 60153.88M 52343.45M 40226.81M
Other liab - - - 894.93M 756.14M
Good will 2482.00M 2422.59M - - -
Other assets - - - 886.04M 804.02M
Cash 25562.09M 3570.88M 19088.95M 3158.24M 4918.20M
Total current liabilities 15648.45M 13983.63M 7291.33M 5820.25M 5125.28M
Current deferred revenue - 853.75M 486.08M 636.57M 1051.81M
Net debt -22424.76M 150.78M -19044.42M -3110.81M -4868.25M
Short term debt 2065.82M 2309.47M 7.09M 2.61M 2.97M
Short long term debt 1915.50M 2132.42M 5.60M 1.12M 1.35M
Short long term debt total 3137.33M 3721.66M 44.53M 47.43M 49.95M
Other stockholder equity 19363.88M 19292.29M 19268.64M 19068.46M 18642.02M
Property plant equipment - - - 16804.03M 12920.38M
Total current assets 67829.38M 56451.52M 69008.08M 58520.79M 51236.42M
Net tangible assets - - - 71450.86M 59032.42M
Short term investments 3960.00M 15816.62M 19273.01M 29268.93M 19546.85M
Net receivables 15165.33M 16482.07M 8715.33M 12514.66M 12726.78M
Long term debt 776.64M 1065.40M 32.61M 38.21M 39.34M
Inventory 16852.18M 16763.34M 19453.00M 11856.67M 12751.68M
Accounts payable 8204.10M 8626.92M 5873.50M 4628.50M 4007.25M
Accumulated other comprehensive income 412.28M -97.05M - - -
Non currrent assets other 921.19M 16659.26M 1064.41M 836.15M 19957.31M
Non current assets total 44419.82M 50160.94M 18767.27M 19815.42M 13724.40M
Capital lease obligations 445.19M 523.84M 6.32M 8.10M 9.26M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments 17047.36M -17569.11M 12081.88M -6117.18M -13575.91M
Change to liabilities - - - 658.46M 1428.17M
Total cashflows from investing activities 17047.36M -17569.11M - -10026.21M -15240.00M
Net borrowings -575.41M -7562.78M - -2.52M -10.16M
Total cash from financing activities -4334.76M -7994.16M 149.19M 348.98M 12384.60M
Change to operating activities - - - -214.91M 5.14M
Net income 6985.26M 7724.60M 10545.82M 16185.52M 13348.10M
Change in cash 21991.21M -15518.07M 15900.75M -1736.43M 3229.66M
Begin period cash flow 3570.88M 19088.95M 3188.20M 4924.63M 1694.97M
End period cash flow 25562.09M 3570.88M 19088.95M 3188.20M 4924.63M
Total cash from operating activities 9147.30M 9967.97M 3639.68M 7907.69M 6049.29M
Issuance of capital stock 24.88M 5.26M 214.96M 385.52M 12418.07M
Depreciation 3778.74M 3445.66M 1467.36M 1102.96M 987.80M
Other cashflows from investing activities 1468.69M 1294.92M - 1308.17M 619.37M
Dividends paid 3294.88M - - - -
Change to inventory -199.18M 6660.77M -7596.33M 895.01M -5188.89M
Change to account receivables 422.88M -3249.55M 1439.97M -4195.70M -602.01M
Other cashflows from financing activities -305.95M -436.64M -64.65M -35.18M -24.56M
Change to netincome - - - -1381.10M -550.55M
Capital expenditures 3845.42M 3899.30M 2231.19M 5221.19M 2287.76M
Change in working capital -60.63M -531.99M -4179.41M -3930.81M -4357.59M
Stock based compensation - - 0.00M 46.21M 155.34M
Other non cash items -1556.07M -670.30M -4194.09M -1352.43M -830.38M
Free cash flow 5301.88M 6068.67M 1408.49M 2686.50M 3761.53M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(INR)
Price
(INR)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GLAND
Gland Pharma Limited		 44.50
1.36%		 3308.40 35.62 51.28 4.86 2.94 4.38 15.50
SUNPHARMA
Sun Pharmaceutical Industries Limited		 -12.10
0.64%		 1890.20 40.32 26.95 7.69 5.50 7.41 23.64
DIVISLAB
Divi's Laboratories Limited		 83.00
0.73%		 11450.00 70.47 - 17.47 11.44 17.33 47.08
TORNTPHARM
Torrent Pharmaceuticals Limited		 -60.90
1.28%		 4700.10 63.48 56.50 11.13 16.39 11.65 35.91
CIPLA
Cipla Limited		 -15.90
1.12%		 1404.00 21.74 19.01 4.23 3.76 4.08 14.00

Profile*

Gland Pharma Limited

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Plot No. 11 & 84, TSIIC Phase: IV, Hyderabad, India, 502307

91 84 5569 9999

https://www.glandpharma.com

4351

Name Title Year Born
Mr. Srinivas Sadu MD, CEO & Director 1969
Mr. Ravi Shekhar Mitra Chief Financial Officer 1977
Mr. Sampath Kumar Pallerlamudi Company Sec. & Compliance Officer 1981
Mr. Ashish Adhikari VP of Operations 1975
Mr. K. V.G.K. Raju Chief Technical Officer 1951
Mr. Sumanta Bajpayee VP of Investor Relations NA
Mr. Susheel Ogra Sr. Gen. Mang. of Sales & Marketing 1967
Ms. Shilpi Sahay Deputy Gen. Mang. of HR 1981
Dr. C. S. Venkatesan Sr. VP of R&D 1971
Dr. Surapanini Sridevi Sr. VP of R&D 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…